A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian cancer when given as ...
Apr 13, 2026
0
4
For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, according to a study presented at the annual ...
Mar 5, 2026
0
4
Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy. The findings, published ...
Mar 4, 2026
0
6
Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination ...
Mar 2, 2026
0
7
Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery ...
Feb 27, 2026
0
7
High-grade astrocytoma, which includes glioblastoma, is a fast-growing, aggressive brain cancer that often returns after the tumor is removed, making it difficult to treat. Patients with recurrent high-grade astrocytoma typically ...
Feb 26, 2026
0
21
New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and aggressive skin cancer, with immunotherapy before surgery can dramatically shrink or even eliminate ...
Jan 29, 2026
0
7
An Italian study published in Nature Medicine provides compelling evidence that fecal microbiota transplantation (FMT) can enhance the effectiveness of immunotherapy in patients with advanced metastatic renal cell carcinoma ...
Jan 28, 2026
0
42
UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how the aggressive cancer ...
Jan 27, 2026
0
13
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly ...
Jan 22, 2026
0
14
